Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation

ROCKVILLE, Md. and SUZHOU, China, Dec. 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-12-19 08:00 8454

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

ROCKVILLE, Md. and SUZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-12-18 08:00 8358

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication

ROCKVILLE, Md. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-12-13 12:56 4854

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

ROCKVILLE, M.D. and SUZHOU, China, Dec. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-12-07 09:00 5259

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-12-06 08:16 5246

Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023

ROCKVILLE, Md. and SUZHOU, China, Dec. 1, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-12-01 12:00 4481

Innovent's MSCI ESG Rating Upgraded to A

ROCKVILLE, Md. and SUZHOU, China, Nov. 30, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-11-30 21:37 9026

Innovent's MSCI ESG Rating Upgraded to A

China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-11-24 08:42 5375

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)

ROCKVILLE, Md. and SUZHOU, China, Nov. 23, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-11-23 08:00 4736

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

ROCKVILLE, Md.and SUZHOU,China, Nov. 22, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2023-11-22 12:40 7491

Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-11-06 08:00 4479

Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

* Mazdutide demonstrates its differentiated advantages as a novel dual agonist of GLP-1 and GCG r...

2023-10-30 08:00 5270

Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration

ROCKVILLE, Md. and SUZHOU, China, Oct. 9, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-10-09 08:00 7329

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

82.4% of patients without prior CAR-T achieving Complete Response (CR) or better ROCKVILLE, Md. and...

2023-09-29 08:00 3966

Innovent Announces 2023 Interim Results and Business Updates

Remarkable achievements with accelerated growth and improved efficiency to underpin sustainable gro...

2023-08-23 19:38 6270

Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-08-17 08:00 4818

Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer

ROCKVILLIE, Md. and SUZHOU, China, Aug. 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-08-08 11:03 4716

Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma

ROCKVILLE, Md. and SUZHOU, China, July 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-07-03 08:00 6205

Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China

ROCKVILLE, Md. and SUZHOU, China, June 26, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-06-26 08:00 4956

Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, June 12, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-06-12 08:00 7331